Clinical Trials Directory

Trials / Completed

CompletedNCT05043883

Automated Assessment of PVI Using a Novel EP Recording System

Automated Assessment of Pulmonary Vein Isolation (PVI) Using a Novel EP Recording System (CathVision Cube® System)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
101 (actual)
Sponsor
CathVision ApS · Industry
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

A prospective, multi-center study with the CathVision Cube® system and the PVI Analyzer software in radiofrequency (RF), cryo-balloon (CB), and Pulse Field Ablation (PFA) procedures.

Detailed description

Subjects with paroxysmal or persistent atrial fibrillation (AF) who are indicated to undergo first pulmonary vein isolation (PVI) procedure and meet all eligibility criteria will be enrolled in the Study. Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the conventional (CE marked) EP recording system. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the automated algorithm for PVI will be performed offline The primary objective is to validate the PVI Analyzer software with a novel EP recording system (CathVision Cube® System) for assisting assessment of isolation status following PVI ablation. The secondary objective is to determine the feasibility of "real-time" assessment of PVI analysis and rhythm dependent performance using the PVI Analyzer and CathVision Cube® System.

Conditions

Interventions

TypeNameDescription
DEVICECathVision Cube® systemIntracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively.

Timeline

Start date
2021-09-15
Primary completion
2022-06-22
Completion
2022-06-22
First posted
2021-09-14
Last updated
2024-08-09
Results posted
2024-08-09

Locations

4 sites across 2 countries: Belgium, France

Source: ClinicalTrials.gov record NCT05043883. Inclusion in this directory is not an endorsement.